RxDoctor Payments Data

Lisa Mayes, DO

Family Medicine · Macon, MONPI 1558651794

Payments from drug & device makers

$4,690in general payments, 2019–2025

Across 286 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$939
  • Amgen$806
  • Novo Nordisk$374
  • Otsuka America Pharmaceutical, Inc.$289
  • AstraZeneca$190
  • Dexcom, Inc.$190
  • plus $2K from 39 others

What the payments were for

  • Food & beverage$4,677100%
  • Entertainment$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,690 in reported general payments places this provider in the 85th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$4,177
Medicare patients
20
Services billed
29

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl48$72,617
OzempicSemaglutide63$71,681
EliquisApixaban53$37,609
MounjaroTirzepatide31$32,794
JanuviaSitagliptin Phosphate34$28,279
JardianceEmpagliflozin33$28,147
RexultiBrexpiprazole25$23,930
XareltoRivaroxaban45$20,518
LinzessLinaclotide32$19,804
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$13,160
Tresiba Flextouch U-200Insulin Degludec12$10,004
MyrbetriqMirabegron30$8,914
Tresiba Flextouch U-100Insulin Degludec13$8,235
FarxigaDapagliflozin Propanediol14$7,938
BelsomraSuvorexant16$7,132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Linzess, Lumigan$939$95,65392 claims
Novo NordiskOzempic$374$71,68163 claims
MerckJanuvia, Belsomra, Janumet Xr$75$39,12573 claims
PfizerEliquis$115$37,60953 claims
Lilly USA, LLCMounjaro$169$32,79431 claims
Boehringer IngelheimJardiance$13$28,14733 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arexvy$79$24,64552 claims
Otsuka America Pharmaceutical, Inc.Rexulti$289$23,93025 claims
Johnson & JohnsonXarelto$109$20,51845 claims
Astellas Pharma US IncMyrbetriq$97$8,91430 claims
AstraZenecaFarxiga$190$7,93814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Macon

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →